| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Veraxa Biotech AG Ordinary Shares$4.38
-1.48 (-25.26%)
Market Cap
-
EPS
-
P/E Ratio
-
Value Trade
-
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
628.51 K
52 Week Range
-
% held by Insiders
-
% held by Institutions
49.68 %
Enterprise Value
-
Total Shares
-
Short %
-
Float Shares
-
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VRXA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
VRXA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VRXA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VRXA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VRXA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
VRXA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-VRXA
Jun 18, 2026VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
VERAXA Biotech has announced successful in vitro proof-of-concept data for its BiTAC-ADC technology platform, which aims to enhance precision in cancer treatment. The company will present this technology at the BIO International Convention, seeking partnerships to further develop its innovative cancer therapies. The platform is designed to minimize off-tumor toxicity while maximizing therapeutic effects.
Read more →-VRXA
Jun 10, 2026VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
VERAXA Biotech AG has completed its business combination with Voyager Acquisition Corp., becoming a publicly traded company on the Nasdaq under the ticker VRXA. The merger enhances VERAXA's financial position with $27.5 million in secured notes and a $50 million share purchase agreement. The company is focused on developing next-generation cancer therapies using its proprietary BiTAC platform, which targets solid tumors with precision.
Read more →-VRXA
May 28, 2026VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
VERAXA Biotech AG has announced a significant financial boost through a $27.5 million senior secured note and a $50 million share purchase agreement. These transactions are aimed at supporting the closing of its business combination with Voyager Acquisition Corp. and advancing its pipeline of next-generation cancer therapies. The company is also preparing for a NASDAQ listing, which is expected to enhance its market presence.
Read more →Competitive Position
How VRXA ranks across every disease it competes inCompetitive Position is a premium feature
See how VRXA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial